Asset

ABT-072

Abbott Laboratories Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (5)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00890318phase1completed2009-04-012009-07-01AbbottA Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
NCT00752687phase1completed2008-09-012009-05-01AbbottA Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults
NCT01081483phase1completed2010-03-012010-06-01AbbottA Study of Single Doses of ABT-072 in Japanese Healthy Male Adults
NCT00947440phase1completed2009-07-012009-08-01AbbottEvaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation
NCT00982826phase1completed2009-09-012009-12-01AbbottSingle and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)